Updates are available Correction dated 2021-03-11
Click to view Correction: https://doi.org/10.1007/s12094-021-02582-0
-
Authors
Mesia, R. http://orcid.org/0000-0002-3785-3563
Iglesias, L.
Lambea, J.
Martínez-Trufero, J.
Soria, A.
Taberna, M.
Trigo, J.
Chaves, M.
García-Castaño, A.
Cruz, J.
- License Information
-
More Information
Article History
Received: 20 November 2020
Accepted: 21 November 2020
First Online: 26 February 2021
Change Date: 11 March 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s12094-021-02582-0
Compliance with ethical standards
:
: Dr. Ricard Mesía Nin: Consulting and advisory role: MERCK, MSD, ROCHE, AMGEN, AstraZeneca, BMS and Nanobiotics. Speaker’s Bureau: MERCK, MSD, and BMS. Research funding: Merck. Dra. Almudena García Castaño: Advisory board: Roche, Novartis, MSD, BMS, Pierre Fabre, Merck. Speaking: Roche, Novartis, MSD, BMS, Pierre Fabre, Merk. Dr. Manuel Chaves Conde: Virtual congress registration: MSD. Registration for congress, travel and stay: Merck. Clinical trial principal investigator: Roche and MSD. Dr. Juan Jesús Cruz Hernández: Advisory role: Merck, MSD, BMS, Novartis. Conferences with fee: Merck, BMS, MSD, Roche, Astra Zeneca, Novartis. Dr. Julio Lambea:No conflict of interests. Dra. Miren Taberna Sanz: Personal fees: AstraZeneca, MSD, BMS, Nanobiotics, Lilly and Merck. Non-financial support: MSD and Merck, outside the submitted work. Dr. José Manuel Trigo Pérez: Advisory role: Takeda, BMS, Merck, MSD, Boehringer. Registration for congress, travel and stay: Astra-Zeneca, BMS, MSD, Roche. Dra. Lara Iglesias: Personal fees: Merck, MSD, BMS, Roche, Lilly, Eisai, Bayer and Sanofi. Dr. Javier Martínez Trufero: No conflict of interests. Dra. Ainara Soria: No conflict of interests.
: This article does not contain any studies with human participants or animals performed by any of the authors.
: For thus type of study formal consent is not required.
